Price$27.47+0.54 (+2.01%)
01:30 PM07:45 PM
News · 26 weeks35+200%
2026-03-012026-08-23
Mix1590d
- Insider5(33%)
- SEC Filings4(27%)
- Other3(20%)
- Earnings2(13%)
- Analyst1(7%)
Latest news
25 items- INSIDERSVP, Strategy & Bus. Dev. Reis Mischa sold $220,000 worth of shares (8,000 units at $27.50) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 27,321 units (SEC Form 4)4 - Envista Holdings Corp (0001757073) (Issuer)
- INSIDERChief Executive Officer Keel Paul A was granted 179,730 shares, increasing direct ownership by 48% to 551,304 units (SEC Form 4)4 - Envista Holdings Corp (0001757073) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Hammes Eric D.4 - Envista Holdings Corp (0001757073) (Issuer)
- SECEnvista Holdings Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - Envista Holdings Corp (0001757073) (Filer)
- INSIDERNew insider Thomas Coree K. claimed ownership of 19,069 shares (SEC Form 3)3 - Envista Holdings Corp (0001757073) (Issuer)
- PRCosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill ItRENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy space, and the industry built around them optimized for predictability and reversibility rather than for biology. That framework is now under real pressure, partly because GLP-1's success in weight loss has expanded the population needing volume restoration at a scale the injectable toolkit was never designed for, and partly because the science moved. When dermatologists, facial plastic surgeons and aesthetic medicine specialists gather this week at the Controversies & Conversation
- SECSEC Form 10-Q filed by Envista Holdings Corporation10-Q - Envista Holdings Corp (0001757073) (Filer)
- SECEnvista Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Envista Holdings Corp (0001757073) (Filer)
- PREnvista Reports Second Quarter 2026 ResultsBREA, Calif., Aug. 5, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended July 3, 2026. "We built on our fast start in Q1 with continued good performance in Q2," said Paul Keel, CEO. "We delivered growth across both our reporting segments and all major geographies. Our focus on operational excellence, underpinned by the Envista Business System, contributed to further margin expansion. Based on our strong first-half performance and continued momentum, we are raising our full year outlook for core sales growth, adjusted EBITDA, and adjusted EPS. We are well-positioned to del
- PREnvista to Host Investor Day on September 17, 2026BREA, Calif., July 28, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will hold an Investor Day on Thursday, September 17, from 9:00 a.m. to noon EDT. This event will include a management presentation followed by a question-and-answer session. The event and corresponding presentation will be webcast live and also available for replay afterwards by visiting the Events and Presentations section of investors.envistaco.com.In-person attendance requires advanced registration. Those interested in attending the event in person can contact IR@envistaco.com for more information
- ANALYSTBMO Capital Markets initiated coverage on Envista with a new price targetBMO Capital Markets initiated coverage of Envista with a rating of Market Perform and set a new price target of $27.00
- PREnvista Schedules Second Quarter 2026 Earnings CallBREA, Calif., July 7, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its second quarter 2026 on Wednesday, August 5, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You can access the conference call by dialing 1-800-83
- SECEnvista Holdings Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Envista Holdings Corp (0001757073) (Filer)
- SECSEC Form SD filed by Envista Holdings CorporationSD - Envista Holdings Corp (0001757073) (Filer)
- INSIDERChief Executive Officer Keel Paul A covered exercise/tax liability with 12,811 shares, decreasing direct ownership by 3% to 371,574 units (SEC Form 4) to satisfy tax liability4 - Envista Holdings Corp (0001757073) (Issuer)
- PRHenry Schein Announces the Election of William K. "Dan" Daniel as Independent Chairman of the BoardHenry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. "Dan" Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired from the Board following 44 years as a Director of Henry Schein and was named Chairman Emeritus in recognition of his extraordinary contributions to the Company. Mr. Daniel joined the Henry Schein Board of Directors in May 2025. He possesses decades of board and global executive leadership experience in healthcare and industrial sectors, including serving for 14
- INSIDERDirector Tsingos Christine A was granted 9,330 shares, increasing direct ownership by 18% to 59,930 units (SEC Form 4)4 - Envista Holdings Corp (0001757073) (Issuer)
- INSIDERDirector Carruthers Wendy was granted 9,330 shares, increasing direct ownership by 18% to 59,940 units (SEC Form 4)4 - Envista Holdings Corp (0001757073) (Issuer)
- INSIDERDirector Raskas Daniel was granted 9,330 shares, increasing direct ownership by 21% to 54,010 units (SEC Form 4)4 - Envista Holdings Corp (0001757073) (Issuer)
- INSIDERDirector Huennekens R Scott was granted 12,585 shares, increasing direct ownership by 18% to 82,105 units (SEC Form 4)4 - Envista Holdings Corp (0001757073) (Issuer)
- INSIDERDirector Pierce James Andrew was granted 9,330 shares, increasing direct ownership by 102% to 18,485 units (SEC Form 4)4 - Envista Holdings Corp (0001757073) (Issuer)
- INSIDERDirector Gallahue Kieran was granted 9,330 shares, increasing direct ownership by 21% to 54,010 units (SEC Form 4)4 - Envista Holdings Corp (0001757073) (Issuer)
- INSIDERDirector Jain Vivek was granted 9,330 shares, increasing direct ownership by 21% to 52,945 units (SEC Form 4)4 - Envista Holdings Corp (0001757073) (Issuer)
- SECEnvista Holdings Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Envista Holdings Corp (0001757073) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Envista Holdings CorporationSCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)
NVST FAQ
7 questionsWhat does Envista Holdings Corporation do?
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera...Where does NVST stock trade?
Envista Holdings Corporation (NVST) is listed on NYSE.What sector and industry is NVST in?
Envista Holdings Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did Envista Holdings Corporation go public?
Envista Holdings Corporation (NVST) completed its IPO in 2019.What are analysts saying about NVST?
Envista Holdings Corporation has had 8 recent analyst actions on file. The most recent action was from BMO Capital Markets: Market Perform with a $2700.00 price target on 2026-07-09. Recent price targets range from $2000.00 to $3500.00.What companies are similar to NVST?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare NVST side-by-side with any of them on Quantisnow.How can I track NVST on Quantisnow?
Quantisnow aggregates Envista Holdings Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVST to receive live email and push alerts on every new disclosure.